Andrew Obenshain, bluebird bio CEO

Blue­bird bio starts 15 pa­tients on its three mul­ti­mil­lion-dol­lar gene ther­a­pies

Blue­bird bio’s stock $BLUE jumped over 20% on Thurs­day fol­low­ing its first-quar­ter earn­ings re­lease and the an­nounce­ment of 15 pa­tients start­ing on its three ap­proved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.